Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

"Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W).~Participants may self-administer injection after proper training."

"Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W).~Participants may self-administer injection after proper training."